A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Buchbinder, Elizabeth I; Gunturi, Anasuya; Perritt, Jessica; Dutcher, Janice; Aung, Sandra; Kaufman, Howard L; Ernstoff, Marc S; Miletello, Girald P; Curti, Brendan D; Daniels, Gregory A; Patel, Sapna P; Kirkwood, John M; Hallmeyer, Sigrun; Clark, Joseph I; Gonzalez, Rene; Richart, John M; Lutzky, Joe; Morse, Michael A; Sullivan, Ryan J; McDermott, David F.

Afiliación

Buchbinder EI; Dana Farber Cancer Institute, Boston, MA USA.
Gunturi A; The Cancer Center - Lowell General Hospital, Lowell, MA 01854 USA.
Perritt J; Prometheus Labs, 9410 Carroll Park Drive, San Diego, CA 92121 USA.
Dutcher J; Cancer Research Foundation of New York, Chappaqua, NY USA.
Aung S; Prometheus Labs, 9410 Carroll Park Drive, San Diego, CA 92121 USA.
Kaufman HL; Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ USA.
Ernstoff MS; Cleveland Clinic, Cleveland, OH USA.
Miletello GP; Hematology/Oncology clinic, Baton Rouge, LA USA.
Curti BD; Providence Health & Services, Portland, OR USA.
Daniels GA; Moores UCSD Cancer Center, La Jolla, CA USA.
Patel SP; The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.
Kirkwood JM; University of Pittsburgh School of Medicine, Pittsburgh, PA USA.
Hallmeyer S; Oncology Specialists, SC, Park Ridge, IL USA.
Clark JI; Loyola Medicine, Maywood, IL USA.
Gonzalez R; University of Colorado, Aurora, CO USA.
Richart JM; Saint Louis University, Saint Louis, MO 63110 USA.
Lutzky J; Mount Sinai Medical Center, Miami Beach, FL USA.
Morse MA; Duke, Durham, NC USA.
Sullivan RJ; Massachusetts General Hospital, Boston, MA USA.
McDermott DF; Beth Israel Deaconess Medical Center, Boston, MA USA.